iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK) assessed ...
GlaxoSmithKline is boosting its cancer drug pipeline through a partnership with iTeos Therapeutics, a deal that gives the pharmaceutical giant a chance to catch up to its peers in the pursuit of a hot ...
Belgian immunotherapy developer iTeos Therapeutics has snagged Sanofi’s cancer drug development leader, Joanne Lager, M.D., to be its new chief medical officer. The hire comes after the company raised ...
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...
Just two weeks after dropping a TIGIT candidate jointly developed with GSK, iTeos has announced plans to wind down operations and explore strategic alternatives. The first half of this year has been ...
iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Roche's accidental disclosure of positive data on its anti-TIGIT ...
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and ...
iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...
Small biotechnology company iTeos Therapeutics could succeed where larger drugmakers have fallen short, should study results it presented Saturday at a cancer research conference hold up in further ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A two-drug regimen involving an experimental cancer ...
Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback